PFE

Summary

Our analysis is Sell/Avoid new longs in PFE at 27.88-27.935. The stock is extended +17.5% in 26 days now testing 10 EMA 27.74 by 0.14 (0.5% buffer < ATR 0.57), risk/reward inverted (~1.23 to Bollinger upper 29.11 vs 0.94 to middle 26.94 and 2.56 to SMA 25.32, only 2.4% to target 28.60/52W high 28.75). We recommend 0 new capital; trim existing longs qualitatively. Tight risk: close below 27.74 = reduce, break of VWMA 27.42 = exit core. Re-entry only on confirmed hold above 27.74 with volume expansion + MACD histogram turning up from 0.07, or mean reversion to 27.42-26.94. Horizon 5 days tactical avoid; IV 50.8% and put/call 2.78 caps upside.

The case

Our analysis is Sell/Avoid for new money. (1) Technicals: uptrend remains intact with price above 10 EMA 27.74, VWMA 27.42, and 10% above 50/200 SMA 25.32, but the move is late-stage and decelerating. RSI 63.49 is cooling, MACD 0.85>0.78 but histogram 0.07 is compressing, and the stock has pulled back 2.4% from the 28.57 high on 31.9M volume to 27.88 on 4.7M partial volume with 0.25 range < ATR 0.57. Risk/reward is inverted with upside capped by Bollinger upper 29.11 and analyst target 28.60 versus downside to middle 26.94 and SMAs 25.32. (2) Sentiment: social sentiment shows retail 5:1 bullish (10 vs 2, confidence 62, greed 58) diverging from institutional hedging where put/call volume is 2.78 (7,753 vs 2,787) at 50.8% IV and OI 0.84 is neutral, indicating a tactical cap for the next 1-4 weeks. (3) Longer-term contrarian case: low-volume digestion, RSI not >70, stable EBITDA 5.6B in Q2 and gross margin 74.7% with EMA validation is valid longer-term but does not justify chasing at highs and relies on a hypothetical 32+ measured move versus the verified target 28.60. (4) Fundamentals are fragile near-term: TTM P/E 36.76 vs forward 9.65 requires an EPS jump from 0.76 to 2.89 that is unproven, Q2 FCF 302M vs 2.451B quarterly dividend was funded by 4.38B investment sales (TTM FCF 12.48B covers 9.8B annual 1.27x but quarterly coverage failed), debt is 63.2B with negative tangible book -33.28B on 118.47B intangibles (59% of assets), recurring impairments of 4.325B in Q2 and 4.47B in Q4 drove GAAP loss -248M despite 3.5B operating income, and filings guide a 1.1B patent expiry hit in 2026 accelerating to 2030. With price only 0.14 above EMA 27.74 and risk/reward already inverted, avoiding new longs is disciplined.

What would weaken it

• Late-stage rally: RSI 63.49 cooling, MACD histogram 0.07 compressing
• Options hedging extreme: put/call 2.78 at 50.8% IV caps upside
• Balance sheet stress: 63.2B debt, -33.28B tangible book, 1.1B patent hit